share_log

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Gibson Christopher

Recursion Pharmaceuticals | 4：持股變動聲明-高管 Gibson Christopher
美股SEC公告 ·  08/27 04:46
牛牛AI助理已提取核心訊息
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, initiated a purchase of 5,000 shares of the company's Class A Common Stock on August 26, 2024. The transaction was carried out at a price of $2.48 per share, reflecting a total investment of $12,400. Following this transaction, Gibson's direct holdings in Recursion Pharmaceuticals increased to a total of 742,656 shares. The transaction is currently in progress and falls under the category of exercising or conversion of derivative security.
Christopher Gibson, Chief Executive Officer of Recursion Pharmaceuticals, initiated a purchase of 5,000 shares of the company's Class A Common Stock on August 26, 2024. The transaction was carried out at a price of $2.48 per share, reflecting a total investment of $12,400. Following this transaction, Gibson's direct holdings in Recursion Pharmaceuticals increased to a total of 742,656 shares. The transaction is currently in progress and falls under the category of exercising or conversion of derivative security.
2024年8月26日，Recursion Pharmaceuticals首席執行官Christopher Gibson以每股2.48美元的價格購買了公司的5,000股A類普通股。此次交易共計投資12,400美元。在此次交易後，Gibson在Recursion Pharmaceuticals的直接持股增加至總共742,656股。該交易目前正在進行中，屬於行使或轉換衍生證券的類別。
2024年8月26日，Recursion Pharmaceuticals首席執行官Christopher Gibson以每股2.48美元的價格購買了公司的5,000股A類普通股。此次交易共計投資12,400美元。在此次交易後，Gibson在Recursion Pharmaceuticals的直接持股增加至總共742,656股。該交易目前正在進行中，屬於行使或轉換衍生證券的類別。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間